UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

(usinington, D.C. 200)

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Date of Report: March 10, 2014 (Date of earliest event reported)

MRI INTERVENTIONS, INC.

(Exact name of registrant as specified in its charter)

000-54575

Delaware

(State or other jurisdiction of incorporation or organization)

(Commission File Number) 58-2394628 (I.R.S. Employer Identification No.)

38103

(Zip Code)

One Commerce Square, Suite 2550 Memphis, Tennessee (Address of principal executive offices)

(901) 522-9300

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

Product Revenues for the Quarter Ended December 31, 2013

MRI Interventions, Inc. (the "Company") recorded product revenues of \$1.1 million for the quarter ended December 31, 2013, compared to \$339,000 for the same period in 2012, an increase of 226%. ClearPoint disposable product revenues were \$562,000 for the quarter ended December 31, 2013, compared with \$308,000 for the same period in 2012, representing growth of 82%. Revenues from ClearPoint system reusable component sales were \$545,000 in the fourth quarter 2013, compared to \$31,000 in the quarter ended December 31, 2012.

Product Revenues for the Year Ended December 31, 2013

The Company recorded product revenues of \$2.9 million for the year ended December 31, 2013, compared to \$1.2 million for the prior year, an increase of 149%. Product revenues included ClearPoint system disposable product sales for the year ended December 31, 2013 of \$1.8 million, compared with \$1.0 million for the prior year, representing growth of 75%. The Company's revenues from sales of ClearPoint system reusable components were \$1.1 million for the year ended December 31, 2013 compared with \$150,000 for the prior year, an increase of \$982,000.

Press Release

On March 10, 2014, the Company issued a press release announcing its product revenues for the quarter and full year ended December 31, 2013. In the press release, the Company also announced that it expects to issue another press release on March 20, 2014 reporting more detailed information regarding the Company's results of operations and financial condition for the quarter and full year ended December 31, 2013. A copy of the press release issued by the Company on March 10, 2014 is furnished herewith as Exhibit 99.1.

All of the foregoing information is furnished by the Company pursuant to Item 2.02 of Form 8-K and will not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index immediately following signature page.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MRI INTERVENTIONS, INC.

By: /s/ Oscar Thomas

Oscar Thomas Vice President, Business Affairs

Date: March 10, 2014

EXHIBIT INDEX

Exhibit No.	Description

99.1 Press Release of the Company dated March 10, 2014

MRI Interventions Announces Quarterly Product Revenues in Excess of \$1 Million for the First Time for the Fourth Quarter of 2013

Full Year Product Revenues Exceed Guidance

MRI Interventions Sets Date to Report Full Financial Results

MEMPHIS, Tenn., March 10, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart, announced today its fourth quarter and full year product revenues for 2013. MRI Interventions also announced the date on which it will release its full financial results for the quarter and year ended December 31, 2013.

Product Revenues

"We are very pleased to have achieved a milestone during the fourth quarter as we recorded product revenues of \$1.1 million, which was the first time our quarterly product revenues exceeded \$1 million," said Kimble Jenkins, CEO of MRI Interventions. "The \$1.1 million in product revenues for the quarter represents more than 200% growth over the fourth quarter of 2012. Our total product revenues for 2013 of \$2.9 million also sets a record, exceeding our previously announced guidance on product revenues of \$2.5 million to \$2.8 million. We look forward to sharing our full results and providing an update on our progress later this month," said Jenkins.

Quarter Ended December 31, 2013

MRI Interventions recorded product revenues of \$1.1 million for the quarter ended December 31, 2013, compared to \$339,000 for the same period in 2012, an increase of 226%. ClearPoint disposable product revenues were \$562,000 for the quarter ended December 31, 2013, compared with \$308,000 for the same period in 2012, representing growth of 82%. Revenues from ClearPoint system reusable component sales were \$545,000 in the fourth quarter 2013, compared to \$31,000 in the quarter ended December 31, 2012.

Year Ended December 31, 2013

MRI Interventions recorded product revenues of \$2.9 million for the year ended December 31, 2013, compared to \$1.2 million for the prior year, an increase of 149%. Product revenues included ClearPoint system disposable product sales for the year ended December 31, 2013 of \$1.8 million, compared with \$1.0 million for the prior year, representing growth of 75%. Revenues from sales of ClearPoint system reusable components were \$1.1 million for the year ended December 31, 2013, compared with \$150,000 for the prior year, an increase of \$982,000.

Release of Full Financial Results for the Quarter and Year Ended December 31, 2013

MRI Interventions will release its fourth quarter and 2013 full year financial results on Thursday, March 20, 2014, after the close of the U.S. financial markets.

MRI Interventions will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the company's results. To listen to the conference call, please dial 877-407-9034 from the United States or Canada or 201-493-6737 from other international locations. A playback of the call will be available through March 27, 2014, and may be accessed by dialing 877-660-6853 from the United States or Canada, or 201-612-7415 from other international locations, and referencing Conference ID 413671. Additionally, you may access the live or archived webcast of the conference call on the Company's website at http://ir.stockpr.com/mriinterventions/ir-calendar.

About MRI Interventions, Inc.

Founded in 1998, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared and CE-marked ClearPoint[®] system is designed to enable a wide range of minimally invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace[®] system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. For more information, please visit <u>www.mriinterventions.com</u>.

Contact Information:

MRI Interventions, Inc. David Carlson, CFO, 901-522-9300